‘Cost-Cutting’ Could Undo Trump Drug Pricing Achievement

The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang for the taxpayers’ buck, writes former FDA Commissioner Scott Gottlieb.